Stopping GLP-1 drugs may increase heart attack, stroke and death risk

People with type 2 diabetes who stop taking GLP-1 medications may carry twice the risk of suffering a heart attack, a stroke or death compared with those who stay on them.

People with type 2 diabetes who stop taking GLP-1 medications may carry twice the risk of suffering a heart attack, a stroke or death compared with those who stay on them. This research involved an analysis of more than 80,000 people with type 2 diabetes and no established heart disease at the start of the project.

Researchers analysed electronic medical records from more than 300 diabetes clinics throughout Italy. The team included experts in Italy and from Guy’s and St Thomas’ NHS Foundation Trust in London. On average, patients who continued treatment took a GLP-1 drug for nearly three years, compared with just over one year for those who stopped.

The risk of a non-fatal heart attack, non-fatal stroke or death from any cause was about twice as high in people who stopped GLP-1 treatment as in those who continued. This was the equivalent of about four strokes or heart attacks per 100 people per year among those who stopped, compared with two per 100 among those who continued. Risks seemed higher in people who were still obese among those who stopped.

Dr Sonya Babu-Narayan, a consultant cardiologist and clinical director at the British Heart Foundation, said these findings suggest people with type 2 diabetes who stop taking GLP-1 medicines may face a higher risk of future heart attack, stroke or death than those who continue treatment. Dr Faye Riley, research communications lead at Diabetes UK, said the findings reinforce the importance of supporting people to stay on treatments that work for them.

The study was observational, and it was possible that people who stopped taking GLP-1 drugs were already in poorer health. Reasons for stopping were not taken into account, but may have been because of side effects, cost, frailty or illness such as cancer. Researchers said the increased risk of death and heart disease found in the study might not be explained just by weight gain or worsening blood sugar.

GLP-1s are known to be beneficial for the heart, as studies suggest they can help reduce inflammation and improve blood-vessel function. When people lose weight, their blood pressure, inflammation and cholesterol levels tend to improve. Juliet Bouverie, chief executive of the Stroke Association, said tackling existing risk factors of stroke, including poor diet, drinking too much alcohol, smoking and not taking regular exercise, remains essential.

Key facts

  • People with type 2 diabetes who stop GLP-1 treatment had about twice the risk of non-fatal heart attack, non-fatal stroke, or death compared to those who continued.
  • The study analysed electronic medical records from more than 300 diabetes clinics throughout Italy.
  • The risk of heart attack or stroke was equivalent to four cases per 100 people per year among those who stopped, compared to two per 100 among those who continued.

Three perspectives

Neutral

An analysis of more than 80,000 patients in Italy found that people with type 2 diabetes who stopped GLP-1 medications had higher risks of heart attack, stroke, or death than those who continued.

Positive

GLP-1 medications are known to be beneficial for the heart, helping to reduce inflammation and improve blood-vessel function.

Negative

People with type 2 diabetes who come off weight-loss jabs may carry twice the risk of suffering a heart attack, a stroke or death compared with those who stay on them.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

Next storyIncreased TV viewing linked to faster kidney function decline

All sections

Edition